Race-associated biological differences among Luminal A breast tumors

Breast Cancer Research and Treatment

Volumn 152, Issue 2, 2015, Pages 437-448

  D’Arcy, Monica ^a,b   Fleming, Jodie ^a   Robinson, Whitney R ^a,b   Kirk, Erin L ^a   Perou, Charles M ^a,b,c   Troester, Melissa A ^a,b,c  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer mortality disparity; Gene expression; Luminal A tumors; Survival

Indexed keywords

MUCIN 1; TUMOR MARKER;

ACOX2 GENE; ADULT; AFRICAN AMERICAN; ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; CRYBB2 GENE; ETHNICITY; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEALTH DISPARITY; HUMAN; LUMINAL A BREAST CANCER; MAJOR CLINICAL STUDY; MALE; MUC1 GENE; PRIORITY JOURNAL; PSPH GENE; RACE; SQLE GENE; TYMS GENE; AGED; BREAST NEOPLASMS; CANCER GRADING; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TUMOR VOLUME; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CLUSTER ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; PROPORTIONAL HAZARDS MODELS; TUMOR BURDEN; YOUNG ADULT;

EID: 84948388427     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3474-4     Document Type: Article

References (41)

1. American Cancer Society (2013) Breast cancer facts and figures 2013–2014. ACS, Atlanta
2. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. doi:10.1001/jama.295.21.2492
3. O’Brien KM, Cole SR, Tse CK et al (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110. doi:10.1158/1078-0432.CCR-10-1533
4. Reeder-Hayes KE, Meyer AM, Dusetzina SB et al (2014) Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. Breast Cancer Res Treat 145:743–751. doi:10.1007/s10549-014-2957-z
5. Albain KS, Unger JM, Crowley JJ et al (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101:984–992. doi:10.1093/jnci/djp175;10.1093/jnci/djp175
6. Field LA, Love B, Deyarmin B et al (2012) Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer 118:1334–1344. doi:10.1002/cncr.26405
7. Grunda JM, Steg AD, He Q et al (2012) Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American women diagnosed with breast cancer. BMC Res Notes 5:248. doi:10.1186/1756-0500-5-248
8. Martin DN, Boersma BJ, Yi M et al (2009) Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One 4:e4531. doi:10.1371/journal.pone.0004531
9. Stewart PA, Luks J, Roycik MD et al (2013) Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer. PLoS One 8:e82460. doi:10.1371/journal.pone.0082460
10. Sun X, Casbas-Hernandez P, Bigelow C et al (2012) Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res Treat 131:1003–1012. doi:10.1007/s10549-011-1789-3
11. Pirone JR, D’Arcy M, Stewart DA et al (2012) Age-associated gene expression in normal breast tissue mirrors qualitative age-at-incidence patterns for breast cancer. Cancer Epidemiol Biomark Prev 21:1735–1744. doi:10.1158/1055-9965.EPI-12-0451
12. Casbas-Hernandez P, Sun X, Roman-Perez E et al (2015) Tumor intrinsic subtype is reflected in cancer-adjacent tissue. Cancer Epidemiol Biomark Prev 24(2):406–414. doi:10.1158/1055-9965.EPI-14-0934
13. Curtis C, Shah SP, Chin SF et al (2012) The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486:346–352. doi:10.1038/nature10983
14. Prat A, Parker JS, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68. doi:10.1186/bcr2635
15. van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009. doi:10.1056/NEJMoa021967
16. Benito M, Parker J, Du Q et al (2004) Adjustment of systematic microarray data biases. Bioinformatics 20:105–114
17. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167. doi:10.1200/JCO.2008.18.1370
18. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article 3. doi:10.2202/1544-6115.1027
19. de Hoon MJ, Imoto S, Nolan J et al (2004) Open source clustering software. Bioinformatics 20:1453–1454. doi:10.1093/bioinformatics/bth078
20. Saldanha AJ (2004) Java Treeview–extensible visualization of microarray data. Bioinformatics 20:3246–3248. doi:10.1093/bioinformatics/bth349
21. Jovov B, Araujo-Perez F, Sigel CS et al (2012) Differential gene expression between African American and European American colorectal cancer patients. PLoS One 7:e30168. doi:10.1371/journal.pone.0030168
22. Wallace TA, Prueitt RL, Yi M et al (2008) Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68:927–936. doi:10.1158/0008-5472.CAN-07-2608
23. Ferguson SE, Olshen AB, Levine DA et al (2006) Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol 101:209–213. doi:10.1016/j.ygyno.2005.11.028
24. Sturgill GM, Bala E, Yaniglos SS et al (2010) Mutation screen of beta-crystallin genes in 274 patients with age-related macular degeneration. Ophthalmic Genet 31:129–134. doi:10.3109/13816810.2010.486774
25. Alers JC, Rochat J, Krijtenburg PJ et al (2000) Identification of genetic markers for prostatic cancer progression. Lab Invest 80:931–942
26. Kim SK, Jung WH, Koo JS (2014) Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes. PLoS One 9:e101004. doi:10.1371/journal.pone.0101004
27. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
28. Johansson A, Curran JE, Johnson MP et al (2011) Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular disease. Eur J Hum Genet 19:796–800. doi:10.1038/ejhg.2011.19
29. Hodo Y, Hashimoto S, Honda M et al (2010) Comprehensive gene expression analysis of 5′-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma. Genomics 95:217–223. doi:10.1016/j.ygeno.2010.01.004
30. Zaretsky JZ, Barnea I, Aylon Y et al (2006) MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression. Mol Cancer 5:57. doi:10.1186/1476-4598-5-57
31. Deng J, Wang L, Chen H et al (2013) The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer Metastasis Rev 32:535–551. doi:10.1007/s10555-013-9423-y
32. Wang L, Ma J, Liu F et al (2007) Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 105:695–702. doi:10.1016/j.ygyno.2007.02.004
33. Li Y, Cozzi PJ (2007) MUC1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets 7:259–271
34. Helms MW, Kemming D, Pospisil H et al (2008) Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease. Br J Cancer 99:774–780. doi:10.1038/sj.bjc.6604556
35. Martinez-Balibrea E, Abad A, Martinez-Cardus A et al (2010) UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 103:581–589. doi:10.1038/sj.bjc.6605776
36. Donada M, Bonin S, Barbazza R et al (2013) Management of stage II colon cancer—the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol 13:36. doi:10.1186/1471-230X-13-36
37. Loganayagam A, Arenas Hernandez M, Corrigan A et al (2013) Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 108:2505–2515. doi:10.1038/bjc.2013.262
38. Lu Y, Zhuo C, Cui B et al (2013) TYMS serves as a prognostic indicator to predict the lymph node metastasis in Chinese patients with colorectal cancer. Clin Biochem 46:1478–1483. doi:10.1016/j.clinbiochem.2013.06.017
39. Yokomise H, Liu D, Chang S et al (2013) Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. Anticancer Res 33:1107–1115
40. Rummel S, Penatzer CE, Shriver CD et al (2014) PSPHL and breast cancer in African American women: causative gene or population stratification? BMC Genet 15:38. doi:10.1186/1471-2156-15-38
41. Sturtz LA, Melley J, Mamula K et al (2014) Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. BMC Cancer 14:62. doi:10.1186/1471-2407-14-62